Andrew Sneddon
CHAIRMAN
Elastagen
Australia
Biography
Andrew was appointed to the Board of Elastagen Pty Ltd as Chairman in September 2008. Andrew is a former partner of PricewaterhouseCoopers (PWC). In his PWC role, Andrew led the technology practise for a period of time and specialised in fast growth and emerging technology companies working with many companies from start-ups to successful global corporations. In more recent years he was the partner leading the firm’s Australian Life Sciences Practice. Andrew has extensive experience in a wide range of technical areas including mergers and acquisitions, business and strategic planning, audit, valuation, capital raising and stock exchange listings on the Australian, NASDAQ and London Stock Exchanges. He has worked across a broad range of industries and is currently a Non-Executive Director of Innate Immunotherapeutics Limited, ClearView Wealth Limited and the Chairman of ServiceRocket Inc, Fusion Payments Limited and TGR BioSciences Pty Ltd. He is also a member of the Audit and Compliance Committees of the Crescent Capital Private Equity Funds.
Research Interest
Pharmaceutics & Biopharmaceutics Drug Targeting & Drug Development Pharmaceutical Research Pharmaceutical Materials Pharmaceutical Formulations Pharmaceutical Biotechnology Pharmaceutical Nanotechnology Pharmaceutical Technology Pharmaceutical Manufacturing Pharmaceutical Engineering Drug Delivery Technologies Medical Devices Drug Regulatory Affairs Pharmaceutical Management
